Document:

Exhibit 10.16.1

 Exhibit 10.16.1 

FOURTH AMENDMENT OF THE 
 LIPOSCIENCE, INC. 2007 STOCK INCENTIVE PLAN 
 THIS FOURTH AMENDMENT to the
LipoScience, Inc. (the “Company”) Stock Incentive Plan (the “Plan”) is effective as of August 27, 2012. 
 WHEREAS, the Board of Directors (the “Board”) of the Company has adopted and the stockholders of the Company have approved the Plan; and 

WHEREAS, the Board has approved the amendment of the Plan in order to increase the number of shares of Common Stock of the Company
issuable pursuant to awards granted under the Plan by 600,000 shares, from 3,308,043 to 3,908,043 shares. 
 NOW, THEREFORE, the
Plan shall be amended as follows: 
 1. The first sentence of Paragraph 4 of the Plan shall be deleted in its entirety and the
following substituted in lieu thereof: 
 “Subject to adjustment under Section 8, Awards may be made
under the Plan for up to 3,908,043 shares of the Common Stock of the Company, $0.001 par value per share (the “Common Stock).” 
 2. Except as amended herein, the terms and provisions of the Plan shall remain unchanged and in full force and effect.Exhibit 10.37

 Exhibit 10.37 
 *** Text Omitted and Filed Separately 
 Confidential Treatment Requested

 Under 17 CFR §§ 200.80(b)(4) and 230.406 

2012 Corporate Goals for Strategic Leadership Team 
 Approved by the Compensation Committee on February 7, 2012 
 Revenue Growth versus Prior
Year (60%) 
  

					
	 Total Revenue Growth Vs. Prior Year
	  	Funding*	 
	 3 [***]% growth
	  	 	200	% 
	 3 [***]% growth
	  	 	175	% 
	 3 [***]% growth
	  	 	150	% 
	 3 [***]% growth
	  	 	125	% 
	 3 [***]% ([***])
	  	 	100	% 
	 3 [***]% growth ([***])
	  	 	50	% 
	 3 [***]% growth
	  	 	25	% 
	 £ [***]% growth
	  	 	No Payout	  

  

	*	Subject to a cash override: must maintain cash above 95% of year-end cash budget—otherwise the achieved revenue payout ($) will be discounted by 20%.

 Vantera Clearance and Launch (30%) 
  

	 	•	 	 Q2: CLIA registration of Vantera (10% weighting) 

  

	 	•	 	 Q2: Internal launch of Vantera for use in reporting clinical commercial results (20% weighting) 

 

	 	•	 	 Q3: FDA clearance (50% weighting) 

  

	 	•	 	 Q4: [***] initial satisfaction levels support positive external references (20% weighting) 

For purposes of these metrics, Q2, Q3, and Q4 are defined as the last day of each respective quarter. 

Furthermore, for each component a 10% increase/decrease in bonus will be applied for beating/missing the timeline goal by 30 days, 20%
increase/decrease for 31 to 60 days, 25% increase/decrease for 61 to 90 days. The bonus amount will be at the discretion of the compensation committee for any overachievement or delay greater than 91 days. 

If Vantera is not FDA approved in 2012, the entire Vantera payout will be zero. 
 Third Component: Successful IPO (10%) 
 While the Board is evaluating several pathways to
ensure that the company is adequately capitalized, the IPO is the clear preference, and this component reflects that desired outcome. 
 The
exact determination of whether the IPO was a successful IPO will be decided by the Board Compensation Committee in consultation with the Pricing Committee following completion of the IPO. 

 

	[***]	Certain confidential information in this document, marked by bracketed asterisks, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 406 promulgated under the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to the omitted portions.EX-10.1

 Exhibit 10.1 

 
 EXECUTION VERSION 

AMENDMENT NO. 4 TO CREDIT AGREEMENT 
 This Amendment (this “Amendment”) is made as of December 13, 2012 among Molex Incorporated, a Delaware corporation (the “Company”), JPMorgan Chase Bank, N.A., individually and as
administrative agent (the “Administrative Agent”), and the other financial institutions signatory hereto. 

R E C I T A L S: 

A.    The Company, the Subsidiary Borrowers party thereto, the Administrative Agent and the Lenders are party to a
Credit Agreement dated as of June 24, 2009 (previously amended, the “Credit Agreement”). Unless otherwise specified herein, capitalized terms used in this Amendment shall have the meanings ascribed to them by the Credit Agreement.

 B.    The Company, the Administrative Agent and the undersigned Lenders wish to amend the Credit Agreement
on the terms and conditions set forth below. 
 Now, therefore, in consideration of the mutual execution hereof and other good
and valuable consideration, the parties hereto agree as follows: 
 1.    Amendments to Credit
Agreement.    Upon the Effective Time (as defined below), the Credit Agreement shall be amended as follows: 
 (a)    Section 1.01 is amended by adding the following new defined terms in the appropriate alphabetical order: 

“MJDI Adverse Judgment” means a judgment that imposes liability on the Company or a Subsidiary for any
of the Molex Japan Disputed Indebtedness. 
 “MJDI Bond” means cash, surety bonds, letters of
credit and/or bank guarantees that are posted by the Company in order to stay an MJDI Adverse Judgment pending the appeal thereof. 
 (b)    Section 5.01(e) is amended in its entirety to read as follows: 
 (e)    within 60 days following the first day of each fiscal year of the Company (but only to the extent prepared by the Company for such fiscal year) a copy of the investor outlook
presentation prepared by the Company for such fiscal year, which shall be accompanied by the statement of a Financial Officer of the Company to the effect that, to the best of his or her knowledge at the time made, such presentation is a reasonable
estimate for the periods covered thereby; and 
 (c)    Section 6.02 is amended by (i) deleting
the word “and” at the end of clause (f); (ii) designating the existing clause (g) as clause (h); and (iii) inserting the following new clause (g) in appropriate sequence: 

(g)    any Lien on cash or cash equivalents (i) that comprise a part of, or that secure, the
obligations of the Company in respect of the MJDI Bond or (ii) that 

 
secure reimbursement obligations of the Company in respect of any surety bond that constitutes all or a portion of the MJDI Bond; provided that the aggregate Dollar Equivalent amount of the
obligations secured by all such Liens shall not exceed 22 billion Japanese yen (plus interest and fees payable in respect of the applicable surety bonds, letters of credit and/or bank guarantees). 

2.    Representations and Warranties of the Company.    The Company represents and
warrants that: 
 (a)    The execution, delivery and performance by the Company of this Amendment have been
duly authorized by all necessary corporate action and that this Amendment is a legal, valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except as the enforcement thereof may be subject to the
effect of any applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally; 
 (b)    Each of the representations and warranties contained in the Credit Agreement (treating this Amendment as a Credit Document for purposes thereof) is true and correct in all
material respects (except that any representation or warranty which is already qualified as to materiality or by reference to Material Adverse Effect is true and correct in all respects) on and as of the date hereof as if made on the date hereof
(except any such representation or warranty that expressly relates to or is made expressly as of a specific earlier date, in which case such representation or warranty is true and correct in all material respects (except that any representation or
warranty which is already qualified as to materiality or by reference to Material Adverse Effect is true and correct in all respects) with respect to or as of such specific earlier date); and 

(c)    No Default has occurred and is continuing. 

3.    Effective Time.    This Amendment shall become effective upon (the “Effective
Time”) (a) the execution and delivery hereof by the Company, the Administrative Agent and the Required Lenders (without respect to whether it has been executed and delivered by all Lenders) and (b) the execution and delivery by the
Company and each of the Subsidiary Guarantors of a Reaffirmation of Guaranty substantially in the form of Exhibit A hereto. In the event the Effective Time has not occurred on or before December 31, 2012, this Amendment shall not become
operative and shall be of no force or effect. 
 4.    Miscellaneous. 

(a)    Except as specifically amended above, the Credit Agreement and the other Credit Documents shall remain in full
force and effect and are hereby ratified and confirmed. 
 (b)    The execution, delivery and effectiveness
of this Amendment shall not operate as a waiver of any right, power or remedy of the Administrative Agent or any Lender under the Credit Agreement or any other Credit Document, or constitute a waiver of any provision of the Credit Agreement or any
other Credit Document. Upon the effectiveness of this Amendment, each reference in the Credit Agreement to “this Agreement”, “hereunder”, “hereof”, “herein” or

  
 2 

 
words of similar import shall mean and be a reference to the Credit Agreement as amended hereby. 
 (c)    Section headings in this Amendment are included herein for convenience of reference only and shall not constitute a part of this Amendment for any other purposes. 

(d)    This Amendment may be executed in any number of counterparts, each of which when so executed shall be deemed
an original but all such counterparts shall constitute one and the same instrument. Delivery of an executed signature page of this Amendment by facsimile transmission or other electronic transmission shall be effective as delivery of manually
executed counterpart hereof. 
 5.    Costs and Expenses.    The Company hereby
affirms its obligation under Section 9.03 of the Credit Agreement to reimburse the Administrative Agent for all reasonable and documented out-of-pocket expenses incurred by the Administrative Agent in connection with the preparation,
negotiation, execution and delivery of this Amendment, including but not limited to the reasonable and documented fees, charges and disbursements of attorneys for the Administrative Agent with respect thereto. 

6.    Governing Law.    This Amendment shall be construed in accordance with and governed
by the law of the State of Illinois. 
  
 [signature pages
follow] 

  
 3 

 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date and year first
above written. 
  
  

			
	MOLEX INCORPORATED
		
	By:	 	 
		
	Its:	 	 

  
  
  

 
 Signature page to Molex Amendment 

  
  

 

			
	 JPMORGAN CHASE BANK, N. A.,
 individually and as Administrative Agent

		
	By:	 	 
		
	Its:	 	 

  
  
  

 
 Signature page to Molex Amendment 

  
  

 

			
	[LENDER]
		
	By:	 	 
		
	Its:	 	 

  
  
  

 
 Signature page to Molex Amendment 

 EXHIBIT A 
 REAFFIRMATION OF GUARANTY 
 Each of the undersigned (a) acknowledges
receipt of a copy of Amendment No. 4 to Credit Agreement (the “Amendment”), amending the Credit Agreement dated as of June 24, 2009 (as previously amended, the “Credit Agreement”), (b) consents to the Amendment and
each of the transactions referenced therein, (c) hereby reaffirms its obligations, as applicable, under the Parent Guaranty and the Subsidiary Guaranty and (d) agrees that all references in any Credit Document to the “Credit
Agreement” shall hereafter mean and be a reference to the Credit Agreement as amended by the Amendment. Capitalized terms used herein, but not otherwise defined herein, shall have the meanings ascribed to such terms in the Credit Agreement.

 Dated as of December [__], 2012 
  

 

			
	 MOLEX INCORPORATED,

a Delaware corporation

		
	By:	 	 
	Name:	 	 
	Title:	 	 

  

			
	 CARDELL CORPORATION,

a Michigan corporation

		
	By:	 	 
	Name:	 	David D. Johnson
	Title:	 	Treasurer

  

			
	 MOLEX INTERNATIONAL, INC.,
 a Delaware corporation

		
	By:	 	 
	Name:	 	David D. Johnson
	Title:	 	Treasurer

  

			
	 MOLEX CV HOLDINGS, INC.,
 a Delaware corporation

		
	By:	 	 
	Name:	 	David D. Johnson
	Title:	 	Treasurer

  
  
  

Signature page to Reaffirmation of Guaranty 

  

			
	 MOLEX CONNECTOR CORPORATION,
 a Delaware corporation

		
	By:	 	 
	Name:	 	David D. Johnson
	Title:	 	Treasurer

  

			
	 MOLEX COPPER FLEX PRODUCTS, INC.,
 a Minnesota corporation

		
	By:	 	 
	Name:	 	David D. Johnson
	Title:	 	Treasurer

  

			
	 WOODHEAD INDUSTRIES, INC.,
 a Delaware corporation

		
	By:	 	 
	Name:	 	David D. Johnson
	Title:	 	Assistant Treasurer

  

			
	 WOODHEAD INTERCONNECT, INC.,
 a Delaware corporation

		
	By:	 	 
	Name:	 	David D. Johnson
	Title:	 	Treasurer

  

			
	 AERO-MOTIVE COMPANY,

a Michigan corporation

		
	By:	 	 
	Name:	 	David D. Johnson
	Title:	 	Vice President

  

			
	 CENTRAL RUBBER COMPANY,
 an Illinois corporation

		
	By:	 	 
	Name:	 	David D. Johnson
	Title:	 	Treasurer

  
  
  

Signature page to Reaffirmation of Guaranty 

  

			
	 DANIEL WOODHEAD COMPANY,
 a Delaware corporation

		
	By:	 	 
	Name:	 	David D. Johnson
	Title:	 	Treasurer

  

			
	 DW HOLDING, L.L.C.,

a Delaware limited liability company

		
	By:	 	 
	Name:	 	David D. Johnson
	Title:	 	Treasurer

  

			
	 WOODHEAD L.P.,
 a
Texas limited partnership

		
	By:	 	 
	Name:	 	David D. Johnson
	Title:	 	Treasurer

  

			
	 POLYMICRO TECHNOLOGIES, LLC,
 a Delaware limited liability company

		
	By:	 	 
	Name:	 	David D. Johnson
	Title:	 	Assistant Treasurer

  

			
	 WH TWO, LLC,
 a
Delaware limited liability company

		
	By:	 	 
	Name:	 	David D. Johnson
	Title:	 	 

  
  
  

 
 Signature page to Reaffirmation of Guaranty

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00211-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00211-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00211-of-00352.parquet"}]]